<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.fiercebiotech.com" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>InterWest Partners</title>
 <link>http://www.fiercebiotech.com/tags/interwest-partners-0</link>
 <description></description>
 <language>en</language>
<item>
 <title>APT Pharma garners $32.5M to complete lung study</title>
 <link>http://www.fiercebiotech.com/story/apt-pharma-garners-32-5m-complete-phase-iii-lung-study/2008-09-30?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FB0</link>
 <description>&lt;p&gt;APT Pharmaceuticals has completed a $32.3 million Series B financing. The round was led by Three Arch Partners and joined by additional new investors InterWest Partners and Pinnacle Ventures. Existing investors Charter Life Sciences, Great Point Partners, Versant Ventures and Vivo Ventures also participated in the round.&lt;/p&gt;
&lt;p&gt;Much of the money is earmarked to complete APT&#039;s pivotal Phase III program evaluating the safety and efficacy of cyclosporine inhalation solution following lung transplantation. The Series B financing will also fund further development of the company&#039;s pipeline programs in serious lung diseases.&lt;/p&gt;
&lt;p&gt;&quot;With this latest financing, we have the team, the strategy and the financial backing necessary to bring inhaled cyclosporine to market and to become a profitable company,&quot; explained Dr. Stephen Dilly, president and CEO of APT Pharmaceuticals. &quot;The support of a group of premier life sciences investors clearly validates our business model and our recent achievements which is especially gratifying during this uncertain time in the financial markets.&quot;&lt;/p&gt;
&lt;p&gt;- check out the &lt;a href=&quot;http://www.fiercebiotech.com/press-releases/apt-pharmaceuticals-secures-32-million-series-b-financing&quot;&gt;APT release&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Related Articles:&lt;br /&gt;&lt;/strong&gt;&lt;a title=&quot;Venture funds hit the brakes on biotech investing&quot; href=&quot;http://www.fiercebiotech.com/story/venture-funds-hit-brakes-biotech-investing/2008-09-03&quot;&gt;Venture funds hit the brakes on biotech investing&lt;/a&gt;&lt;br /&gt;&lt;a title=&quot;Economy catches up with biotech investing&quot; href=&quot;http://www.fiercebiotech.com/story/economy-catches-biotech-investing/2008-08-29&quot;&gt;Economy catches up with biotech investing&lt;/a&gt;&lt;br /&gt;&lt;a title=&quot;InterWest closes $650M fund&quot; href=&quot;http://www.fiercebiotech.com/story/interwest-closes-650m-fund/2008-08-11&quot;&gt;InterWest closes $650M fund&lt;/a&gt;&lt;br /&gt;&lt;a title=&quot;APT lands $22M in first round&quot; href=&quot;http://www.fiercebiotech.com/story/apt-lands-22m-first-round/2007-10-04&quot;&gt;APT lands $22M in first round&lt;/a&gt;&amp;nbsp;(Oct 2007)&lt;/p&gt;</description>
 <comments>http://www.fiercebiotech.com/story/apt-pharma-garners-32-5m-complete-phase-iii-lung-study/2008-09-30#comments</comments>
 <category domain="http://www.fiercebiotech.com/tags/apt-pharmaceuticals">APT Pharmaceuticals</category>
 <category domain="http://www.fiercebiotech.com/tags/interwest-partners-0">InterWest Partners</category>
 <category domain="http://www.fiercebiotech.com/tags/venture-capitalists">Venture Capital</category>
 <pubDate>Tue, 30 Sep 2008 11:19:07 -0400</pubDate>
 <dc:creator>John Carroll</dc:creator>
 <guid isPermaLink="false">36926 at http://www.fiercebiotech.com</guid>
</item>
<item>
 <title>InterWest closes $650M fund</title>
 <link>http://www.fiercebiotech.com/story/interwest-closes-650m-fund/2008-08-11?utm_medium=rss&amp;utm_source=rss&amp;cmp-id=OTC-RSS-FB0</link>
 <description>&lt;p&gt;Life science VC firm InterWest Partners has closed a $650 million fund. The money will be invested in emerging life sciences and information technology investments. The group aims to invest in&amp;nbsp;25 to 30 new companies, and will focus on &lt;a href=&quot;http://www.fiercebiotech.com/story/funding-gap-threatens-early-stage-r-d-work/2008-07-21&quot;&gt;early-stage companies&lt;/a&gt;&amp;nbsp;in the U.S.&lt;/p&gt;
&lt;p&gt;&quot;For 29 years InterWest has been making successful investments by combining the deep domain experience of our investment team with the vision of outstanding entrepreneurs,&quot; said Dr. Arnold L. Oronsky, general partner at InterWest. &quot;We take pride in our collaborative approach to working with portfolio companies to develop important life sciences and IT products that produce thriving businesses.&quot; In addition to closing the fund, InterWest announced that Chris Ehrlich, Nina Kjellson and Doug Pepper have been promoted to general partner.&lt;/p&gt;
&lt;p&gt;- check out &lt;a href=&quot;http://www.fiercebiotech.com/press-releases/interwest-partners-announces-closing-650-million-venture-fund&quot;&gt;InterWest&#039;s release&lt;/a&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Related Articles:&lt;br /&gt;&lt;/strong&gt;&lt;a title=&quot;Versant closes $500M fund for early-stage research&quot; href=&quot;http://www.fiercebiotech.com/story/versant-closes-500m-fund-early-stage-research/2008-08-01&quot;&gt;Versant closes $500M fund for early-stage research&lt;/a&gt;&lt;br /&gt;&lt;a title=&quot;$117M venture firm takes flight in Europe&quot; href=&quot;http://www.fiercebiotech.com/story/117m-venture-firm-takes-flight-in-europe/2008-04-30&quot;&gt;$117M venture firm takes flight in Europe&lt;/a&gt;&lt;br /&gt;&lt;a href=&quot;http://www.fiercebiotech.com/story/funding-gap-threatens-early-stage-r-d-work/2008-07-21&quot;&gt;&amp;lsquo;Funding gap&#039; threatens early stage R&amp;amp;D work&lt;/a&gt;&lt;/p&gt;</description>
 <comments>http://www.fiercebiotech.com/story/interwest-closes-650m-fund/2008-08-11#comments</comments>
 <category domain="http://www.fiercebiotech.com/tags/interwest-partners-0">InterWest Partners</category>
 <category domain="http://www.fiercebiotech.com/tags/venture-capitalists">Venture Capital</category>
 <category domain="http://www.fiercebiotech.com/tags/venture-capital-fund-0">Venture Capital fund</category>
 <pubDate>Mon, 11 Aug 2008 21:11:37 -0400</pubDate>
 <dc:creator>Maureen Martino</dc:creator>
 <guid isPermaLink="false">32934 at http://www.fiercebiotech.com</guid>
</item>
</channel>
</rss>
